AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Northwest Biotherapeutics, Inc.
Video analysis: NWBO
All videosNo video analysis for this stock yet. Request one from our team.
News: NWBO
Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company
Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company
Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company
SPIMACO is One of the Largest Saudi Pharma Companies and a Leader in 21 Markets Across the MENA Region BETHESDA, Md., Aug. 6, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has entered into a non-binding Memorandum of Understanding (MOU) with the Saudi Pharmaceutical Industries and Medical Appliance Company (SPIMACO) for a collaboration to bring the Company's DCVax®-L products and technology to Saudi Arabia.
Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses
Scientific Presentation at British Neuro-Oncology Annual Meeting Shows Original Analysis of Survival Extension Was Likely Underestimated BETHESDA, Md., July 8, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that the Company's Chief Technical Officer, Dr. Marnix Bosch, presented updated survival data from the Phase III trial of DCVax®-L for glioblastoma (GBM) at the 2026 Annual Meeting of the British Neuro-Oncology Society (BNOS).
Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting
/PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax personalized immune therapies for
Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting
BETHESDA, Md., July 2, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, the Company's Chief Technical Officer, will be making a scientific presentation entitled "DCVax-L–Associated Survival Extension Assessed Through Propensity Score Matching Analyses" at the 2026 Annual Meeting of the British Neuro-Oncology Society (BNOS).
